Hopwood Financial Services Inc. Takes $418,000 Position in Amgen Inc. (NASDAQ:AMGN)

Hopwood Financial Services Inc. bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,605 shares of the medical research company's stock, valued at approximately $418,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP bought a new position in Amgen in the 3rd quarter worth approximately $25,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in Amgen during the third quarter worth $29,000. Synergy Investment Management LLC acquired a new position in Amgen during the 4th quarter valued at $34,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $36,000. Institutional investors own 76.50% of the company's stock.

Insider Activity

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 in the last quarter. Company insiders own 0.69% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Jefferies Financial Group restated a "buy" rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Royal Bank of Canada reissued an "outperform" rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Truist Financial decreased their price objective on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $314.04.

Remove Ads

Amgen Price Performance

NASDAQ AMGN opened at $318.89 on Wednesday. The stock has a market cap of $171.31 billion, a price-to-earnings ratio of 42.24, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The business has a 50 day simple moving average of $288.66 and a 200 day simple moving average of $299.43. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.